Ask about this productRelated genes to: CYP2A7 antibody
- Gene:
- CYP2A7 NIH gene
- Name:
- cytochrome P450 family 2 subfamily A member 7
- Previous symbol:
- -
- Synonyms:
- CYP2A
- Chromosome:
- 19q13.2
- Locus Type:
- gene with protein product
- Date approved:
- 1995-12-13
- Date modifiied:
- 2015-12-09
- Gene:
- CYP2A7P1 NIH gene
- Name:
- cytochrome P450 family 2 subfamily A member 7 pseudogene 1
- Previous symbol:
- -
- Synonyms:
- CYP2A18PN, CYP2A7PT
- Chromosome:
- 19q13.2
- Locus Type:
- pseudogene
- Date approved:
- 1995-12-13
- Date modifiied:
- 2017-03-23
Related products to: CYP2A7 antibody
Related articles to: CYP2A7 antibody
- Although various susceptibility genes have been revealed to influence tobacco smoking, the underlying regulatory mechanisms between genetic variants and smoking are poorly understood. In this study, we investigated -expression quantitative trait loci (-eQTLs) and methylation quantitative trait loci (mQTLs) for 56 candidate smoking-linked genes using the BrainCloud cohort samples. An eQTL was revealed to significantly affect expression in the European sample and two mQTLs were respectively detected in CpG sites in and . Interestingly, we found for the first time that the minor allele of the single nucleotide polymorphism (SNP) rs3745277 located in (downstream of ) significantly decreased methylation at the CpG site for (cg25427638; = 5.31 × 10), reduced expression of ( = 0.03), and lowered the percentage of smokers (8.8% vs. 42.3%; Odds Ratio (OR) = 0.14, 95% Confidence Interval (CI): 0.02-0.62; = 4.47 × 10) in a dominant way for the same cohort sample. Taken together, our findings resulted from analyzing genetic variation, DNA methylation, mRNA expression, and smoking status together using the same participants revealed a regulatory mechanism linking mQTLs to the smoking phenotype. Moreover, we demonstrated the presence of different regulatory effects of low-frequency and common variants on mRNA expression and DNA methylation. - Source: PubMed
Publication date: 2022/08/18
Yang ZhongliYang JiekunMao YingLi Ming D - Our knowledge of pharmacogenetic variability in diverse populations is scarce, especially in sub-Saharan Africa. To bridge this gap in knowledge, we characterised population frequencies of clinically relevant pharmacogenetic traits in two distinct South African population groups. We genotyped 211 tagging single nucleotide polymorphisms (tagSNPs) in 12 genes that influence antiretroviral drug disposition, in 176 South African individuals belonging to two distinct population groups residing in the Western Cape: the Xhosa (n = 109) and Cape Mixed Ancestry (CMA) (n = 67) groups. The minor allele frequencies (MAFs) of eight tagSNPs in six genes (those encoding the ATP binding cassette sub-family B, member 1 [ABCB1], four members of the cytochrome P450 family [CYP2A7P1, CYP2C18, CYP3A4, CYP3A5] and UDP-glucuronosyltransferase 1 [UGT1A1]) were significantly different between the Xhosa and CMA populations (Bonferroni p < 0.05). Twenty-seven haplotypes were inferred in four genes (CYP2C18, CYP3A4, the gene encoding solute carrier family 22 member 6 [SLC22A6] and UGT1A1) between the two South African populations. Characterising the Xhosa and CMA population frequencies of variant alleles important for drug transport and metabolism can help to establish the clinical relevance of pharmacogenetic testing in these populations. - Source: PubMed
Ikediobi OgechiAouizerat BradleyXiao YuanyuanGandhi MonicaGebhardt StefanWarnich Louise